Clinical characteristics, use and switch of drugs for obstructive airway diseases among patients with COPD experiencing an exacerbation: a retrospective analysis of Italian administrative healthcare data.
Cardiovascular Diseases
Chronic Obstructive Pulmonary Disease
Delivery of Health Care
Disease Exacerbation
Pharmaceutical Services
Retrospective studies
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
22 Oct 2024
22 Oct 2024
Historique:
received:
16
02
2024
accepted:
10
10
2024
medline:
23
10
2024
pubmed:
23
10
2024
entrez:
22
10
2024
Statut:
epublish
Résumé
Chronic obstructive pulmonary disease (COPD) represents an important health challenge, despite being preventable and manageable thanks to up-to-date recommendations. In Italy, the pharmaceutical care of COPD patients is still ill-timed and inaccurate. This study aimed to describe the treatment of COPD patients in Italy and possible switches following an exacerbation. This observational retrospective analysis of Italian administrative healthcare data from the Fondazione Ricerca e Salute (ReS) database identified patients aged ≥ 45 years with COPD in 2019 and 2020. At least 6 years of look-back period and absence of concomitant asthma were required. COPD patients were categorized by treatment (SI-single/MI-multiple inhalers, TT-triple therapy, DT-dual therapy, other respiratory treatments, untreated) at index date (first dispensation during accrual period). Occurrence of moderate/severe exacerbation during one-year preceding index date and treatments during one-year preceding the exacerbation (possible switch) were evaluated. From ~ 4.7 million beneficiaries of the Italian National Health Service in 2019 and 2020, respectively, 105,828 and 103,729 (43 and 41 × 1,000 inhabitants aged ≥ 45 years) were identified as having COPD. Of 2019/2020 patients: 3.4%/5.2% received SI-TT, 20.7%/17.5% MI-TT, 35.9%/38.1% DT, 33.0%/33.1% other treatments, and 7.0%/6.0% were untreated. Males were prevalent and median age was > 73 years for all groups. Of 2019/2020 cohorts, heart failure and coronary artery disease affected 24/20%, 18/17%, and 11%/16% patients with SI-TT, MI-TT, DT, and other treatments, respectively. A previous moderate/severe exacerbation (2019/2020 patients) occurred to 60.5%/56.6%, 39.9%/37.4%, 30.8%/29.2% and 31.9%/29.7% patients treated with SI-TT, MI-TT, DT, and other treatments, respectively. Of 2019/2020 patients experiencing moderate/severe exacerbation: 6.0%/7.0% receiving DT, 5.1%/7.0% receiving other treatments and 4.5%/10.0% untreated, switched to SI-TT; 23.7%/16.9% receiving DT, 21.4%/17.7% receiving other treatments and 15.4%/12.0% untreated, switched to MI-TT. COPD patients receiving TT were older and had more comorbidities, especially cardiovascular diseases, than patients receiving DT or other treatments. The limited number of patients switching after exacerbation suggests that many COPD patients may be inappropriately treated. Ensuring early and adequate treatment, combination of in-hospital and outpatient management, and integration of specialist and primary care is pivotal for the appropriate clinical management of COPD patients.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic obstructive pulmonary disease (COPD) represents an important health challenge, despite being preventable and manageable thanks to up-to-date recommendations. In Italy, the pharmaceutical care of COPD patients is still ill-timed and inaccurate. This study aimed to describe the treatment of COPD patients in Italy and possible switches following an exacerbation.
METHODS
METHODS
This observational retrospective analysis of Italian administrative healthcare data from the Fondazione Ricerca e Salute (ReS) database identified patients aged ≥ 45 years with COPD in 2019 and 2020. At least 6 years of look-back period and absence of concomitant asthma were required. COPD patients were categorized by treatment (SI-single/MI-multiple inhalers, TT-triple therapy, DT-dual therapy, other respiratory treatments, untreated) at index date (first dispensation during accrual period). Occurrence of moderate/severe exacerbation during one-year preceding index date and treatments during one-year preceding the exacerbation (possible switch) were evaluated.
RESULTS
RESULTS
From ~ 4.7 million beneficiaries of the Italian National Health Service in 2019 and 2020, respectively, 105,828 and 103,729 (43 and 41 × 1,000 inhabitants aged ≥ 45 years) were identified as having COPD. Of 2019/2020 patients: 3.4%/5.2% received SI-TT, 20.7%/17.5% MI-TT, 35.9%/38.1% DT, 33.0%/33.1% other treatments, and 7.0%/6.0% were untreated. Males were prevalent and median age was > 73 years for all groups. Of 2019/2020 cohorts, heart failure and coronary artery disease affected 24/20%, 18/17%, and 11%/16% patients with SI-TT, MI-TT, DT, and other treatments, respectively. A previous moderate/severe exacerbation (2019/2020 patients) occurred to 60.5%/56.6%, 39.9%/37.4%, 30.8%/29.2% and 31.9%/29.7% patients treated with SI-TT, MI-TT, DT, and other treatments, respectively. Of 2019/2020 patients experiencing moderate/severe exacerbation: 6.0%/7.0% receiving DT, 5.1%/7.0% receiving other treatments and 4.5%/10.0% untreated, switched to SI-TT; 23.7%/16.9% receiving DT, 21.4%/17.7% receiving other treatments and 15.4%/12.0% untreated, switched to MI-TT.
CONCLUSIONS
CONCLUSIONS
COPD patients receiving TT were older and had more comorbidities, especially cardiovascular diseases, than patients receiving DT or other treatments. The limited number of patients switching after exacerbation suggests that many COPD patients may be inappropriately treated. Ensuring early and adequate treatment, combination of in-hospital and outpatient management, and integration of specialist and primary care is pivotal for the appropriate clinical management of COPD patients.
Identifiants
pubmed: 39438812
doi: 10.1186/s12890-024-03339-5
pii: 10.1186/s12890-024-03339-5
doi:
Substances chimiques
Bronchodilator Agents
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
525Informations de copyright
© 2024. The Author(s).
Références
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Prevention, Diagnosis and Management of COPD: 2023 Report. https://goldcopd.org/2023-gold-report-2/ .
Sethi S, Palli SR, Bengtson LGS, Buysman EK, Clark B, Sargent A, et al. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol. J Manag Care Spec Pharm. 2023;29(7):791–806.
pubmed: 37133429
Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd CM, et al. Pharmacologic management of chronic obstructive pulmonary disease. An Official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–69.
doi: 10.1164/rccm.202003-0625ST
pubmed: 32283960
pmcid: 7193862
Sansbury LB, Lipson DA, Bains C, Anley GA, Rothnie KJ, Ismaila AS. Disease burden and healthcare utilization among patients with Chronic Obstructive Pulmonary Disease (COPD) in England. Int J Chron Obstruct Pulmon Dis. 2022;17:415–26.
doi: 10.2147/COPD.S336158
pubmed: 35264848
pmcid: 8901413
Hillas G, Perlikos F, Tzanakis N. Acute exacerbation of COPD: is it the “stroke of the lungs”? Int J Chron Obstruct Pulmon Dis. 2016;11:1579–86.
doi: 10.2147/COPD.S106160
pubmed: 27471380
pmcid: 4948693
Alcázar-Navarrete B, Jamart L, Sánchez-Covisa J, Juárez M, Graefenhain R, Sicras-Mainar A. Clinical characteristics, treatment persistence, and outcomes among patients with COPD treated with single- or multiple-inhaler triple therapy: a retrospective analysis in Spain. Chest. 2022;162(5):1017–29.
doi: 10.1016/j.chest.2022.06.033
pubmed: 35787391
Agenzia Italiana del Farmaco. G.U. n.207 del 30.08.2021. Istituzione della Nota AIFA 99 relativa alla prescrizione, a carico del Servizio sanitario nazionale, della terapia inalatoria di mantenimento con LABA, LAMA, ICS e relative associazioni precostituite (LABA/ICS, LABA/LAMA, LABA/LAMA/ICS) nei pazienti con BPCO. Establishment of Nota AIFA 99 concerning the prescription charged to the Italian National Healthcare Service, of the maintenance therapy with LABA, LAMA, ICS and related pre-established associations. 2021. https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2021-08-30&atto.codiceRedazionale=21A05094&elenco30giorni=false .
Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2021;203(1):24-36.
Sethi S, Clark B, Bengtson LGS, Buysman EK, Palli S, Sargent A, et al. Healthcare resource utilization, cost and Clinical Outcomes in Patients Diagnosed with COPD initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol based on exacerbation history. Int J Chron Obstruct Pulmon Dis. 2023;18:625–41.
doi: 10.2147/COPD.S386962
pubmed: 37155497
pmcid: 10122846
Di Marco F, Santus P, Terraneo S, Peruzzi E, Muscianisi E, Ripellino C, et al. Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study. NPJ Prim Care Respir Med. 2017;27(1):51.
doi: 10.1038/s41533-017-0051-9
pubmed: 28883469
pmcid: 5589801
Vetrano DL, Zucchelli A, Bianchini E, Cricelli C, Piraino A, Zibellini M, et al. Triple inhaled therapy in COPD patients: determinants of prescription in primary care. Respir Med. 2019;154:12–7.
doi: 10.1016/j.rmed.2019.05.022
pubmed: 31202120
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: 2019 Report. 2019. https://goldcopd.org/archived-reports/ .
Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, et al. Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021;203(1):24–36.
doi: 10.1164/rccm.202009-3533SO
pubmed: 33146552
pmcid: 7781116
Italian Institute of Statistics (ISTAT). Anni 2002-2018. Ricostruzione della popolazione residente, per sesso, età e Comune. [Years 2002-2018. The reconstruction of resident population, by sex, age and district]. 2021. https://www.istat.it/it/ .
European Parliament and Council of the European Union. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. 2014. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32014R0536 .
European Parliament and Council of the European Union. Regulation (EU) 2016/679 of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). 2016. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32016R0679 .
Garante per la protezione dei dati personali [Authority for the protection of personal data]. Provvedimento recante le prescrizioni relative al trattamento di categorie particolari di dati, ai sensi dell’art. 21, comma 1 del d.lgs. 10 agosto 2018, n. 101 [Provision for the processing of particular categories of data]. Gazzetta Ufficiale [Official Gazette] Serie Generale n.176 del 29 luglio 2019. https://www.garanteprivacy.it/home/docweb/-/docweb-display/docweb/9124510 .
Italian Ministry of Health. Decreto 30 novembre 2021. Misure volte a facilitare e sostenere la realizzazione degli studi clinici di medicinali senza scopo di lucro e degli studi osservazionali e a disciplinare la cessione di dati e risultati di sperimentazioni senza scopo di lucro a fini registrativi, ai sensi dell'art. 1, comma 1, lettera c), del decreto legislativo 14 maggio 2019, n. 52. (22A01189). Gazzetta Ufficiale [Official Gazette] Serie Generale n. 42 del 19 febbraio 2022. https://www.gazzettaufficiale.it/eli/id/2022/02/19/22A01189/sg .
Biffi A, Comoretto R, Arfe A, Scotti L, Merlino L, Vaghi A, et al. Can healthcare utilization data reliably capture cases of chronic respiratory diseases? a cross-sectional investigation in Italy. BMC Pulm Med. 2017;17(1):20.
doi: 10.1186/s12890-016-0362-6
pubmed: 28103865
pmcid: 5248488
Ferrara R, Ientile V, Piccinni C, Pasqua A, Pecchioli S, Fontana A, et al. Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting. NPJ Prim Care Respir Med. 2018;28(1):10.
doi: 10.1038/s41533-018-0077-7
pubmed: 29572448
pmcid: 5865126
Calabria S, Ronconi G, Dondi L, Piccinni C, Pedrini A, Esposito I, et al. Open triple therapy for chronic obstructive pulmonary disease: Patterns of prescription, exacerbations and healthcare costs from a large Italian claims database. Pulm Pharmacol Ther. 2020;61:101904-.
doi: 10.1016/j.pupt.2020.101904
pubmed: 32092473
Bloom CI, Elkin SL, Quint JK. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016. Int J Chron Obstruct Pulmon Dis. 2019;14:279–87.
doi: 10.2147/COPD.S190086
pubmed: 30774325
pmcid: 6349076
Barnes PJ, Burney PG, Silverman EK, Celli BR, Vestbo J, Wedzicha JA, et al. Chronic obstructive pulmonary disease. Nat Rev Dis Primers. 2015;1:15076.
doi: 10.1038/nrdp.2015.76
pubmed: 27189863
Negewo NA, Gibson PG, McDonald VM. COPD and its comorbidities: Impact, measurement and mechanisms. Respirology. 2015;20(8):1160–71.
doi: 10.1111/resp.12642
pubmed: 26374280
Roy CM, Bollman EB, Carson LM, Northrop AJ, Jackson EF, Moresky RT. Assessing the indirect effects of COVID-19 on healthcare delivery, utilization and health outcomes: a scoping review. Eur J Public Health. 2021;31(3):634–40.
doi: 10.1093/eurpub/ckab047
pubmed: 33755130
Deslee G, Fabry-Vendrand C, Poccardi N, Thabut G, Eteve Pitsaer C, Coriat A, et al. Use and persistence of single and multiple inhaler triple therapy prescribed for patients with COPD in France: a retrospective study on THIN database (OPTI study). BMJ Open Respir Res. 2023;10(1):e001585.
doi: 10.1136/bmjresp-2022-001585
pubmed: 37263738
pmcid: 10255131
Calzetta L, Ritondo BL, de Marco P, Cazzola M, Rogliani P. Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. Expert Rev Respir Med. 2021;15(1):143–52.
doi: 10.1080/17476348.2020.1816830
pubmed: 32856967
Agenzia Italiana del Farmaco. Osservatorio Nazionale sull’impiego dei Medicinali. L’uso dei Farmaci in Italia. Rapporto Nazionale Anno 2019. Roma: Agenzia Italiana del Farmaco, 2020 [The Medicines Utilisation Monitoring Centre. National Report on Medicines use in Italy. Year 2019. Rome: Italian Medicines Agency, 2020]. https://www.aifa.gov.it/rapporti-osmed .
Bansal S, Anderson M, Anzueto A, Brown N, Compton C, Corbridge TC, et al. Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD. NPJ Prim Care Respir Med. 2021;31(1):29.
doi: 10.1038/s41533-021-00241-z
pubmed: 34035312
pmcid: 8149706